The COVID-19 laboratory response in Timor-Leste; a story of collaboration.
COVID-19
Collaboration
Laboratory response
Low-resource
Pandemic
SARS-CoV-2
Timor-Leste
Journal
The Lancet regional health. Southeast Asia
ISSN: 2772-3682
Titre abrégé: Lancet Reg Health Southeast Asia
Pays: England
ID NLM: 9918419282806676
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
01
09
2022
revised:
18
11
2022
accepted:
05
01
2023
entrez:
6
2
2023
pubmed:
7
2
2023
medline:
7
2
2023
Statut:
ppublish
Résumé
Timor-Leste is a small nation of 1.3 million people which shares a land border with Indonesia and is 550 km from Darwin, Australia. It is one of the poorest nations in Asia. The National Health Laboratory (NHL) and its network of smaller laboratories in Timor-Leste had limited capacity to perform molecular diagnostic testing before the coronavirus disease 2019 (COVID-19) pandemic began. With the support of international development partners, the NHL rapidly expanded its molecular testing service. From March 2020 to February 2022, over 200,000 molecular tests were performed; COVID-19 testing sites were established in hospital and community health center laboratories and all 13 municipalities, and the number of scientists and technicians at the molecular diagnostic laboratory at the NHL increased from five to 28 between 2019 and 2022. Molecular diagnostic testing for COVID-19 was successfully established at the NHL and in the municipalities. The molecular diagnostic laboratory at NHL is now equipped to respond to not only large-scale COVID-19 testing but also laboratory detection of other infectious diseases, preparing Timor-Leste for future outbreaks or pandemics.
Identifiants
pubmed: 36744276
doi: 10.1016/j.lansea.2023.100150
pii: S2772-3682(23)00010-0
pmc: PMC9883004
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100150Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
Crown Copyright © 2023 Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
None declared.
Références
BMJ Qual Saf. 2021 Apr;30(4):331-335
pubmed: 33139342
Trans R Soc Trop Med Hyg. 2023 Apr 3;117(4):313-315
pubmed: 36482768
Biol Proced Online. 2021 Sep 30;23(1):19
pubmed: 34592917
Med J Aust. 2020 Jun;212(10):457-458
pubmed: 32401351
Int J Infect Dis. 2022 Jun;119:80-86
pubmed: 35358723
Commun Dis Intell (2018). 2022 Sep 26;46:
pubmed: 36154658
WHO South East Asia J Public Health. 2020 Sep;9(2):134-140
pubmed: 32978346
Front Public Health. 2021 Jul 19;9:705031
pubmed: 34350153
Genes (Basel). 2022 Sep 27;13(10):
pubmed: 36292618
PLoS One. 2020 Nov 11;15(11):e0236849
pubmed: 33175841
Lancet Reg Health West Pac. 2022 Jan;18:100321
pubmed: 34841379
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387